Your browser doesn't support javascript.
loading
SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection.
Chaouat, Abigael Eva; Achdout, Hagit; Kol, Inbal; Berhani, Orit; Roi, Gil; Vitner, Einat B; Melamed, Sharon; Politi, Boaz; Zahavy, Eran; Brizic, Ilija; Lenac Rovis, Tihana; Alfi, Or; Wolf, Dana; Jonjic, Stipan; Israely, Tomer; Mandelboim, Ofer.
Afiliación
  • Chaouat AE; The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), The Hebrew University Hadassah Medical School, Jerusalem, Israel.
  • Achdout H; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.
  • Kol I; The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), The Hebrew University Hadassah Medical School, Jerusalem, Israel.
  • Berhani O; The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), The Hebrew University Hadassah Medical School, Jerusalem, Israel.
  • Roi G; The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), The Hebrew University Hadassah Medical School, Jerusalem, Israel.
  • Vitner EB; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.
  • Melamed S; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.
  • Politi B; Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.
  • Zahavy E; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona, Israel.
  • Brizic I; Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
  • Lenac Rovis T; Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
  • Alfi O; Lautenberg Center for General and Tumor Immunology, The Hebrew University Faculty of Medicine, Jerusalem, Israel.
  • Wolf D; Clinical Virology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Jonjic S; Lautenberg Center for General and Tumor Immunology, The Hebrew University Faculty of Medicine, Jerusalem, Israel.
  • Israely T; Clinical Virology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Mandelboim O; Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
PLoS Pathog ; 17(12): e1010175, 2021 12.
Article en En | MEDLINE | ID: mdl-34929007
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Recombinantes de Fusión / Inmunoglobulina G / Fragmentos Fc de Inmunoglobulinas / Dominios Proteicos / Enzima Convertidora de Angiotensina 2 / SARS-CoV-2 Límite: Animals / Female / Humans Idioma: En Revista: PLoS Pathog Año: 2021 Tipo del documento: Article País de afiliación: Israel
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Recombinantes de Fusión / Inmunoglobulina G / Fragmentos Fc de Inmunoglobulinas / Dominios Proteicos / Enzima Convertidora de Angiotensina 2 / SARS-CoV-2 Límite: Animals / Female / Humans Idioma: En Revista: PLoS Pathog Año: 2021 Tipo del documento: Article País de afiliación: Israel